NLS Pharmaceutics AG: NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice

ZURICH, SWITZERLAND / ACCESSWIRE / November 14, 2022 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and

Related Keywords

Switzerland ,Zurich ,Züsz ,Swiss ,Alex Zwyer ,Cindy Rizzo ,Nasdaq Hearings Panel The ,Exchange Commission ,Nasdaq Stock Market ,European Medicines Agency ,Drug Administration ,Nasdaq ,Pharmaceutics Ltd ,Nasdaq Hearings Panel ,Listing Rule ,Exception Period ,Orphan Disease Designation ,Mazindol Controlled Release ,Orphan Drug Designations ,Pharmaceutics ,Uccessfully ,Appeals ,Elisting ,Notice ,